http://www.fpnotebook.com/
DipyridamoleAka: Persantine, Aggrenox
- Indications
- Cerebrovascular Accident Prevention
- Alternative for Aspirin sensitive patient
- Use Dipyridamole alone (Aggrenox contains Aspirin)
- Mechanism
- Inhibits platelet aggregation
- Dipyridamole acts at platelet phosphodiesterase
- Dosing
- Dipyridamole (Persantine)
- Dose: 75 mg PO qid
- Aggrenox (Dipyridamole 200 mg and Aspirin 25 mg)
- Dose: 1 capsule bid
- Dipyridamole (Persantine)
Dipyridamole (C0012582) | |
|---|---|
| Definition (MSH) | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) |
| Definition (CSP) | platelet inhibitor and coronary vasodilator used to prevent thromboembolism associated with mechanical heart valves, as prophylactic adjunct in the prevention of myocardial reinfarction, and as a diagnostic aid adjunct in myocardial perfusion imaging; administered orally and intravenously. |
| Definition (NCI) | A drug that prevents blood cell clumping and enhances the effectiveness of fluorouracil and other chemotherapeutic agents. |
| Definition (PDQ) | A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties. Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39229&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39229&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C445" NCI Thesaurus) |
| Definition (NCI) | A synthetic agent derivative of pyrimido-pyrimidine, with antiplatelet properties. Dipyridamole inhibits adenosine uptake by platelets and endothelial cells, triggering an accumulation of cyclic adenosine monophosphate (cAMP), and inhibiting the stimulation of platelet aggregation by agents such as platelet activating factor and collagen. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D004176 |
| English | Dipyramidole, Dipyridamole, DIPYRIDAMOLE PREPARATION, DP |
| Spanish | dipiridamol |
| Parent Concepts | piperidine (C0031959), Coronary vasodilator (C0596385), Pyrimidines (C0034289), Radiation-Protective Agents (C0034540), Radiation-Sensitizing Agents (C0034541), Multidrug Resistance Modulator (C0596326), Platelet Aggregation Inhibitors (C0032177), Vasodilator Agents (C0042402), Antiplatelet Agents (C0085826), Drug allergen (C1320237) |
| Sources | CSP, LNC, MSH, MTH, MTHFDA, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Persantine (C0700020) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D004176 |
| English | Boehringer Ingelheim Brand of Dipyridamole, Persantin, Persantine |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
Aggrenox (C0732282) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C405568 |
| English | Aggrenox |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
